Cargando…
Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML
BACKGROUND: The impact of the dose intensity administered in consolidation in Latin America is unknown. This study aimed to evaluate the relative dose intensity (RDI) in consolidation and its impact in overall survival. METHODS: A retrospective study of 86 patients with AML who were diagnosed betwee...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333041/ https://www.ncbi.nlm.nih.gov/pubmed/32670373 http://dx.doi.org/10.1155/2020/8021095 |
_version_ | 1783553664601817088 |
---|---|
author | Ballesteros-Ramírez, Ricardo Quijano, Sandra Solano, Julio Ordoñez-Reyes, Camila Herrera, María V. Murillo, Raúl Fiorentino, Susana Arevalo-Zambrano, Mónica |
author_facet | Ballesteros-Ramírez, Ricardo Quijano, Sandra Solano, Julio Ordoñez-Reyes, Camila Herrera, María V. Murillo, Raúl Fiorentino, Susana Arevalo-Zambrano, Mónica |
author_sort | Ballesteros-Ramírez, Ricardo |
collection | PubMed |
description | BACKGROUND: The impact of the dose intensity administered in consolidation in Latin America is unknown. This study aimed to evaluate the relative dose intensity (RDI) in consolidation and its impact in overall survival. METHODS: A retrospective study of 86 patients with AML who were diagnosed between 2010 and 2016 with a 2-year follow-up in a fourth-level Colombian hospital was carried out. Clinical characteristics were reported, Kaplan-Meier was used for estimating the overall survival, and Cox regression was used for multivariate analysis. RESULTS: The median overall survival (OS) was 20.83 months, and the median event-free survival (EFS) was 16.83 months. 64.3% of the patients achieved remission after the 7 + 3 chemotherapy induction treatment. Patients under 30 years of age, with white blood cell counts less than 100.000 cells/mm3 who responded to induction treatment had a better OS. Additionally, patients receiving an RDI greater than 0.75 of the planned consolidation dose had better survival. The prognostic variables with impact in the OS were the leukocyte count in peripheral blood at diagnosis, the RDI in consolidation treatment with HIDAC and the response obtained after induction. CONCLUSION: This retrospective study allowed us to know the epidemiology of AML in a reference Colombian Hospital. Additionally, in our knowledge, it is the first study that reports the RDI in consolidation with HIDAC in Latin America as a prognostic factor that directly impacts the OS. |
format | Online Article Text |
id | pubmed-7333041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-73330412020-07-14 Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML Ballesteros-Ramírez, Ricardo Quijano, Sandra Solano, Julio Ordoñez-Reyes, Camila Herrera, María V. Murillo, Raúl Fiorentino, Susana Arevalo-Zambrano, Mónica J Cancer Epidemiol Research Article BACKGROUND: The impact of the dose intensity administered in consolidation in Latin America is unknown. This study aimed to evaluate the relative dose intensity (RDI) in consolidation and its impact in overall survival. METHODS: A retrospective study of 86 patients with AML who were diagnosed between 2010 and 2016 with a 2-year follow-up in a fourth-level Colombian hospital was carried out. Clinical characteristics were reported, Kaplan-Meier was used for estimating the overall survival, and Cox regression was used for multivariate analysis. RESULTS: The median overall survival (OS) was 20.83 months, and the median event-free survival (EFS) was 16.83 months. 64.3% of the patients achieved remission after the 7 + 3 chemotherapy induction treatment. Patients under 30 years of age, with white blood cell counts less than 100.000 cells/mm3 who responded to induction treatment had a better OS. Additionally, patients receiving an RDI greater than 0.75 of the planned consolidation dose had better survival. The prognostic variables with impact in the OS were the leukocyte count in peripheral blood at diagnosis, the RDI in consolidation treatment with HIDAC and the response obtained after induction. CONCLUSION: This retrospective study allowed us to know the epidemiology of AML in a reference Colombian Hospital. Additionally, in our knowledge, it is the first study that reports the RDI in consolidation with HIDAC in Latin America as a prognostic factor that directly impacts the OS. Hindawi 2020-06-24 /pmc/articles/PMC7333041/ /pubmed/32670373 http://dx.doi.org/10.1155/2020/8021095 Text en Copyright © 2020 Ricardo Ballesteros-Ramírez et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ballesteros-Ramírez, Ricardo Quijano, Sandra Solano, Julio Ordoñez-Reyes, Camila Herrera, María V. Murillo, Raúl Fiorentino, Susana Arevalo-Zambrano, Mónica Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML |
title | Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML |
title_full | Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML |
title_fullStr | Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML |
title_full_unstemmed | Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML |
title_short | Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML |
title_sort | influence of dose intensity in consolidation with hidac and other clinical and biological parameters in the survival of aml |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333041/ https://www.ncbi.nlm.nih.gov/pubmed/32670373 http://dx.doi.org/10.1155/2020/8021095 |
work_keys_str_mv | AT ballesterosramirezricardo influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml AT quijanosandra influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml AT solanojulio influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml AT ordonezreyescamila influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml AT herreramariav influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml AT murilloraul influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml AT fiorentinosusana influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml AT arevalozambranomonica influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml |